Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $1.4 million.

  • Cumberland Pharmaceuticals' Prepaid Assets fell 2941.44% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 2941.44%. This contributed to the annual value of $2.8 million for FY2024, which is 789.14% down from last year.
  • Cumberland Pharmaceuticals' Prepaid Assets amounted to $1.4 million in Q3 2025, which was down 2941.44% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Prepaid Assets peaked at $3.7 million during Q3 2022, and registered a low of $1.3 million during Q3 2021.
  • Moreover, its 5-year median value for Prepaid Assets was $2.3 million (2024), whereas its average is $2.4 million.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Prepaid Assets soared by 19694.61% in 2022, and later crashed by 4727.88% in 2023.
  • Cumberland Pharmaceuticals' Prepaid Assets (Quarter) stood at $3.3 million in 2021, then fell by 7.63% to $3.1 million in 2022, then decreased by 1.94% to $3.0 million in 2023, then decreased by 7.89% to $2.8 million in 2024, then tumbled by 50.57% to $1.4 million in 2025.
  • Its Prepaid Assets was $1.4 million in Q3 2025, compared to $1.6 million in Q2 2025 and $2.2 million in Q1 2025.